|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:approvalYear
|
2023
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:J07BX08
|
|
gptkbp:brand
|
gptkb:Abrysvo
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:contains
|
gptkb:RSV_prefusion_F_protein_antigen
|
|
gptkbp:form
|
suspension for injection
|
|
gptkbp:indication
|
adults 60 years and older
pregnant individuals (to protect infants)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:pregnancyCategory
|
approved for use in pregnancy (in some regions)
|
|
gptkbp:protectionDuration
|
at least one RSV season
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
muscle pain
injection site pain
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:respiratory_syncytial_virus_(RSV)
|
|
gptkbp:usedFor
|
prevention of respiratory syncytial virus (RSV)
|
|
gptkbp:website
|
https://www.abrysvo.com/
|
|
gptkbp:bfsParent
|
gptkb:RSV
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abrysvo
|